What NVIDIA's 2026 Healthcare AI Survey Actually Shows

NVIDIA's 2026 healthcare and life sciences survey reports that 70% of respondents said their organizations were actively using AI, up from 63% in the previous survey. The finding points to broader operational use, but it should be read correctly: it is a vendor-sponsored survey of industry professionals, not an audit of every healthcare organization or proof that any particular AI system improves patient outcomes.

The most useful takeaway is that respondents reported value from narrowly defined applications—medical imaging, drug discovery, workflow optimization, virtual assistants, and administrative work—while privacy, data quality, evaluation, and clinical accountability remain essential constraints.

What the survey measured

NVIDIA's second annual State of AI in Healthcare and Life Sciences report summary was based on responses from more than 600 professionals across healthcare and life sciences. Its questions covered AI use, generative and agentic AI, return on investment, open-source tools, budgets, and deployment barriers.

Because respondents describe their own organizations, figures about adoption, revenue, and cost are self-reported. They indicate sentiment and reported experience within the sample; they do not establish clinical efficacy or causation. “AI helped increase revenue,” for example, is different from a controlled analysis proving that AI alone produced the increase.

Key findings at a glance

Finding	Reported result	How to interpret it
Organizations actively using AI	70% of respondents, up from 63%	Adoption within the survey sample, not the entire global sector
Using generative AI and large language models	69%, up from 54%	Use can include administrative and research workloads; it does not necessarily mean autonomous clinical decisions
Using or assessing agentic AI	47%	Combines deployed systems and systems still under evaluation
Open source rated moderately to extremely important	82%	Shows strategic interest, not automatic suitability for regulated deployment
Executives reporting revenue benefit	85%	Self-reported business impact among surveyed executives
Executives reporting cost reduction	80%	Self-reported impact that requires organization-specific verification
Respondents expecting AI budgets to rise	85%	Planned spending, not guaranteed deployment or return

For more background on AI tools and implementation choices, see TipsMake's artificial intelligence guides.

Generative AI use is expanding

Generative AI and large language models were the most frequently reported workload, cited by 69% of respondents. Data analytics and data science ranked next, followed by predictive analytics. Agentic AI appeared as a newer category, with 47% saying their organizations were using or assessing agents.

Digital healthcare led the industry segments in active AI use at 78%, followed by medical technology at 74%, according to NVIDIA's published summary. These segment figures should not be mixed with workload percentages: an organization can use several workloads at the same time.

Across the whole sample, clinical decision support, medical imaging, and workflow optimization were the leading use cases. “Clinical decision support” generally means helping a qualified professional review information or identify an area of concern; it should not be described as replacing a clinician or independently diagnosing a patient.

Targeted applications produced the clearest reported ROI

The strongest return-on-investment results were attached to specific workflows rather than an undefined “AI transformation.” Among medical-technology respondents, 57% identified medical imaging as an area where AI produced ROI. Among pharmaceutical and biotechnology respondents, 46% named drug discovery and development as a leading ROI use case.

The leading reported ROI area for digital healthcare was virtual health assistants and chatbots, cited by 37%. For payers and providers—including hospitals, primary-care providers, and insurers—39% identified administrative tasks and workflow optimization as the top area.

These results support a practical implementation pattern:

1. Choose one costly or slow workflow with a clear owner.
2. Measure its current time, error rate, cost, and service outcome.
3. Test AI on representative data, including difficult and minority cases.
4. Keep a human decision point wherever an error could affect care, eligibility, or safety.
5. Compare the pilot with the baseline and record failures, not only successes.
6. Scale only if the measured benefit survives privacy, security, integration, and staffing costs.

An operational gain does not automatically imply a clinical gain. A documentation assistant may reduce time without improving diagnostic accuracy; an imaging tool may help prioritize studies but still require validation for its intended population and clinical setting.

Agentic AI adds capability and risk

Agentic AI systems can plan or execute multi-step work using tools and data sources. In the NVIDIA survey, 47% of respondents said they were using or evaluating agents. Reported applications included knowledge retrieval, research-document analysis, and internal process optimization.

An agent that only summarizes approved literature has a different risk profile from one that writes to a patient record, schedules care, submits an insurance decision, or changes a treatment workflow. Organizations should define separate controls for each tool and action:

• use least-privilege identities rather than shared administrator accounts;
• separate read access from permission to write, send, delete, or approve;
• prevent untrusted emails, documents, and webpages from silently changing the agent's instructions;
• log the source data, model version, tool calls, output, reviewer, and final action;
• require explicit human approval for clinical, financial, and patient-facing consequences;
• test recovery procedures for incorrect output, compromised credentials, and service outages.

Healthcare data should not be pasted into a consumer chatbot simply because the interface is convenient. TipsMake's guide to AI data and training controls explains why model-training settings, retention, memory, and connected-app permissions must be reviewed separately.

Open source can improve control, but not remove obligations

Eighty-two percent of respondents rated open-source software and models as moderately to extremely important to their AI strategy. Open tools can support inspection, customization, deployment in a controlled environment, and reproducible research. They do not automatically make a system private, secure, accurate, or compliant.

A healthcare organization still needs to examine the model license, training-data documentation, dependencies, update process, cybersecurity controls, performance across relevant patient groups, and the people responsible for monitoring the system. Self-hosting also transfers patching, access control, logging, backups, and incident response to the operator.

TipsMake's security guides cover general account and system protections, but a regulated healthcare deployment also needs specialist clinical, privacy, legal, and security review.

Clinical use requires evidence beyond a business survey

A survey about adoption and ROI cannot establish whether a medical product is safe or effective. In the United States, the FDA maintains an AI-enabled medical device list that links to authorization information. The FDA notes that the list is not comprehensive, and marketing authorization applies to a device's stated intended use—not every possible use of the underlying model.

The World Health Organization's guidance on large multimodal models in health emphasizes governance, transparency, human rights, safety, and accountability. Those concerns apply throughout the system lifecycle:

• Before deployment: define the intended use, excluded uses, responsible owner, affected population, evidence threshold, and fallback process.
• During validation: test accuracy, calibration, bias, usability, security, and workflow effects with representative local data.
• In production: monitor drift, errors, overrides, complaints, access logs, and outcomes; communicate limitations to users.
• After changes: revalidate when the model, prompt, data pipeline, interface, or clinical workflow materially changes.

What leaders should take from the report

The survey provides credible evidence that AI has moved beyond isolated experiments for many respondents and that budgets are likely to continue rising. It also shows why “adopt AI” is not a useful project objective. The better question is whether a particular system improves a defined workflow for a defined population, with evidence strong enough for the consequences of failure.

Start with a bounded problem, measure a baseline, protect patient data, validate the full human-and-software workflow, and keep accountable professionals in control. Reported adoption and ROI can justify careful evaluation; they cannot substitute for clinical evidence, regulatory review, or ongoing monitoring.